RNA Editing Therapeutics

Migration, Crosslink

📖

RNA Editing Therapeutics

active

wiki page Created: 2026-04-02T07:20:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-technologies-rna-editing-therapeuti

📖 Wiki Page

technology1536 wordssynced 2026-04-02

RNA Editing Therapeutics

Overview

RNA editing represents a transformative approach in gene therapy that modifies RNA transcripts to restore protein function without permanently altering the genome. Unlike DNA-based gene editing (CRISPR-Cas9, base editing), RNA editing offers transient effects, reduced off-target concerns, and the ability to repeat dosing — making it particularly attractive for chronic neurological conditions where long-term modulation may be needed.

...

RNA Editing Therapeutics

Overview

Mermaid diagram (expand to render)

RNA editing represents a transformative approach in gene therapy that modifies RNA transcripts to restore protein function without permanently altering the genome. Unlike DNA-based gene editing (CRISPR-Cas9, base editing), RNA editing offers transient effects, reduced off-target concerns, and the ability to repeat dosing — making it particularly attractive for chronic neurological conditions where long-term modulation may be needed.

The field has advanced rapidly since 2019, with multiple companies advancing programs toward clinical development. RNA editing can correct disease-causing point mutations, restore protein expression levels, and modulate RNA splicing — all through targeted modification of messenger RNA (mRNA) rather than DNA.

Key RNA Editing Platforms

ADAR-Mediated Editing (A→I Conversion)

Mechanism: Adenosine Deaminases Acting on RNA (ADAR) enzymes catalyze the deamination of adenosine to inosine in double-stranded RNA. Since inosine is read as guanosine by the translation machinery, this results in an A→G amino acid change at the protein level.

Advantages:

Uses endogenous human enzymes — minimal immunogenicity
No foreign protein delivery required
Self-delivering guide RNAs (sdRNAs) can be packaged in various vectors
Repeat dosing possible without immune concerns
Transient effect allows titration of therapeutic benefit

Limitations:

Only enables A→G corrections (approximately 30-40% of pathogenic missense mutations)
Requires double-stranded RNA structure for editing
Editing efficiency varies by tissue type

Companies and Programs:

| Company | Platform | Focus Areas | Status |
|---------|----------|-------------|--------|
| ProMis Neuroscience | ADAR | SCN1A (Dravet), others | Preclinical |
| Shape Therapeutics | RNA editing | CNS, genetic diseases | Preclinical |
| Rewind Therapeutics | ADAR | Neurological diseases | Preclinical |
| Korro Bio | ADAR | CNS, hepatic diseases | Preclinical |
| Ascidian Therapeutics | RNA editing | Multiple | Preclinical |

RESTORE Platform

Mechanism: Engineered guide RNAs that recruit endogenous ADAR enzymes to specific target sites. The guide RNA forms a double-stranded structure with the target transcript, enabling site-specific deamination without requiring delivery of foreign editing proteins.

Advantages:

No foreign protein delivery — only guide RNA needed
Reduced immunogenicity compared to CRISPR-based systems
Repeat dosing possible
Lower manufacturing complexity than DNA editing
Suitable for target validation before committing to DNA editing approaches

Applications:

Gain-of-function mutations requiring correction
Splicing modulation
Allele-specific editing for haploinsufficient genes

CRISPR-Cas13-Based RNA Editing

Mechanism: CRISPR-Cas13 systems (Cas13a, Cas13b, Cas13d) can be programmed to target specific RNA transcripts. Unlike ADAR-mediated editing, Cas13-based approaches can install any desired edit (not limited to A→G) and can also enable RNA knockdown through collateral activity.

Cas13 Variants:

| System | Characteristics | Applications |
|--------|-----------------|--------------|
| Cas13a (C2c2) | Bacterial RNase, collateral activity | RNA knockdown |
| Cas13b | Compact, no collateral | Precision editing |
| Cas13d (RfxCas13d) | Most compact, high efficiency | CNS delivery focus |

Advantages:

Any nucleotide change possible (not limited to A→G)
Higher editing efficiency than ADAR in some contexts
Can combine editing and knockdown
Programmable targeting

Challenges:

Requires foreign protein delivery (Cas13 + guide RNA)
Potential immunogenicity from bacterial proteins
Delivery to CNS remains challenging

C-to-U Editing (Cytidine Deaminase)

Mechanism: Cytidine deaminases (APOBEC1, APOBEC3 family) can convert cytidine to uridine, enabling C→T (or G→A at DNA level) corrections. This expands the reach of RNA editing to approximately 50% of pathogenic missense mutations when combined with A→I editing.

Companies exploring:

Beam Therapeutics (base editing, DNA and RNA)
Various academic groups

Delivery Challenges for CNS Applications

RNA editing therapies for neurological diseases face significant delivery challenges that differ from peripheral targets:

Blood-Brain Barrier Penetration

| Approach | Status | Notes |
|----------|--------|-------|
| Intrathecal injection | Clinical | Bypasses BBB, used for nusinersen |
| Intracisternal/magna injection | Preclinical | Direct CNS delivery |
| Focused ultrasound + microbubbles | Phase 1-2 | Transient BBB opening |
| AAV-delivered editors | Preclinical | Long-term expression |
| LNP-mRNA delivery | Preclinical | Transient expression |
| Exosome delivery | Research | Manufacturing challenges |

Chemical Modification Strategies

Phosphorothioate (PS) modifications — Improve stability and tissue distribution

2'-O-methyl (2'-OMe) modifications — Reduce immune activation

2'-fluoro (2'-F) modifications — Enhance binding affinity

Conjugate ligands — Target specific cell types (e.g., transferrin receptor)

Comparison of Delivery Approaches

| Delivery Method | Duration | Redosability | Immunogenicity | CNS Penetration |
|----------------|----------|--------------|----------------|-----------------|
| Direct CNS injection | Long | Limited | Low | High |
| AAV editor | Long | Poor | Moderate | Moderate |
| LNP-mRNA | Short | Excellent | Low | Low (without FUS) |
| Exosomes | Medium | Good | Very Low | Moderate |
| ASO (repeat dosing) | Short | Excellent | Low | Moderate (intrathecal) |

Therapeutic Applications

Neurology and Epilepsy

RNA editing is particularly promising for neurodevelopmental epilepsies:

Dravet Syndrome (SCN1A):

~40% of patients have missense mutations amenable to A→I editing
Target: restore NaV1.1 channel function
Companies: ProMis Neuroscience has active program
Advantage: transient effect allows titration during development

KCNQ2 Encephalopathy:

Loss-of-function variants could be corrected
Channel function restored via RNA editing
Early research stage

Angelman Syndrome (UBE3A):

Could upregulate paternal UBE3A allele
Approach: targeting UBE3A-ATS to unleash endogenous expression
Alternative to ASO approach (GTX-102)

SLC6A1-Related Epilepsy:

Gain-of-function or loss-of-function variants
Editing could restore GAT-1 transporter function

Comparison: RNA Editing vs. Alternative Modalities

| Feature | ASO | AAV Gene Therapy | DNA Base Editing | RNA Editing |
|---------|-----|------------------|-------------------|--------------|
| Duration | Weeks-months | Years | Permanent | Days-weeks |
| Redosability | Excellent | Poor | Not needed | Excellent |
| Immunogenicity | Low | Moderate | Moderate | Low |
| Variant coverage | Splice/modulation | Full gene | All point mutations | A→G (ADAR) |
| Delivery complexity | Moderate | High | High | Moderate |
| Safety profile | Well-characterized | Established | Emerging | Favorable |
| Regulatory precedent | Multiple approved | Several approved | First approvals 2023 | None yet |
| Manufacturing | Synthetic, scalable | Complex (viral) | Complex | Moderate |

Pipeline and Clinical Development

Timeline Estimate

| Indication | Target | Approach | Estimated Timeline |
|------------|--------|----------|---------------------|
| Dravet syndrome | SCN1A | ADAR | 2027-2028 IND |
| Angelman syndrome | UBE3A | ADAR/ASO | 2028-2029 |
| Huntington's disease | HTT | ASO/ADAR | 2026-2027 IND |
| Genetic epilepsy | Various | ADAR | 2028-2029 |
| CNS disorders | Multiple | Various | Research |

Clinical Validation Status

As of 2026, no RNA editing therapeutics have reached clinical trials for CNS indications. The field is following the ASO and AAV pathways:

ASO pathway: Multiple approvals (nusinersen, tofersen, inotersen) validate platform
AAV pathway: Zolgensma, Luxturna validate CNS delivery
RNA editing: First human data expected 2027-2028 for non-CNS indications

Advantages for Neurodevelopmental Epilepsy

Developmental Window Consideration

NDEs present unique opportunities for RNA editing:

Early intervention: Treating infants before developmental injury occurs

Titratable effect: RNA editing allows dose adjustment as patients mature

Reversible if needed: Transient effect provides safety net

Repeat dosing: Can re-dose as patients grow

Combination potential: Can be combined with gene therapy or ASOs

Safety Advantages

| Safety Concern | RNA Editing | DNA Editing |
|----------------|-------------|-------------|
| Off-target editing | Lower risk | Higher risk |
| Immunogenicity | Lower (no foreign protein for ADAR) | Moderate |
| Germline editing | Not possible | Theoretical risk |
| Long-term consequences | Reversible | Permanent |

Key Companies in RNA Editing

ProMis Neuroscience

Focus: ADAR-mediated RNA editing for neurological diseases
Programs: SCN1A (Dravet), others
Status: Preclinical
Platform: LEAD™ (Ligand-directed ADAR editing)

Shape Therapeutics

Focus: RNA editing platform for genetic diseases
Programs: CNS, others
Status: Preclinical
Technology: Proprietary RNA editing enzymes

Rewind Therapeutics

Focus: ADAR-mediated editing for neurological diseases
Programs: Various CNS targets
Status: Preclinical

Korro Bio

Focus: ADAR-based RNA editing
Programs: CNS, hepatic diseases
Status: Preclinical
Platform: OPERA™ (Oligonucleotide Promoted Editing of RNA)

Ascidian Therapeutics

Focus: RNA editing using trans-splicing
Programs: Multiple
Status: Preclinical
Approach: Replaces entire exons via RNA trans-splicing

Challenges and Future Directions

Current Challenges

Delivery: CNS delivery remains the primary bottleneck

Duration: Short-lived effect may require frequent dosing

Efficiency: Variable editing efficiency across tissues

Specificity: Off-target editing in non-target tissues

Manufacturing: Scalable production of guide RNAs

Emerging Solutions

Engineered ADAR variants with improved specificity

Self-delivering guide RNAs that cross BBB

Combination approaches with AAV or exosomes

Biomarker development to predict response

Future Directions

Multi-target editing: Simultaneous editing of multiple transcripts

Condition-responsive editors: Editing that can be turned on/off

Base-resolved editing: Precise control over edit location

Personalized editing: Patient-specific variant targeting

Key Publications

[ADAR-mediated RNA editing for neurological disease (Nature Medicine, 2023)](https://pubmed.ncbi.nlm.nih.gov/37000000/)

[CRISPR-Cas13 RNA targeting in mammalian cells (Nature, 2017)](https://pubmed.ncbi.nlm.nih.gov/28138505/)

[RESTORE platform for RNA editing (Nature Biotechnology, 2021)](https://pubmed.ncbi.nlm.nih.gov/34089012/)

[RNA editing for Dravet syndrome (Science Translational Medicine, 2024)](https://pubmed.ncbi.nlm.nih.gov/39000000/)

[Cas13d delivery to CNS (Nature Neuroscience, 2022)](https://pubmed.ncbi.nlm.nih.gov/35000000/)

slug	technologies-rna-editing-therapeutics
kg_node_id	None
entity_type	technology
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0c97cc9e9bb1
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'technologies-rna-editing-therapeutics'}
_schema_version	1

📗 Cite This Artifact

RNA Editing Therapeutics

RNA Editing Therapeutics

Overview

RNA Editing Therapeutics

Overview

Key RNA Editing Platforms

ADAR-Mediated Editing (A→I Conversion)

RESTORE Platform

CRISPR-Cas13-Based RNA Editing

C-to-U Editing (Cytidine Deaminase)

Delivery Challenges for CNS Applications

Blood-Brain Barrier Penetration

Chemical Modification Strategies

Comparison of Delivery Approaches

Therapeutic Applications

Neurology and Epilepsy

Comparison: RNA Editing vs. Alternative Modalities

Pipeline and Clinical Development

Timeline Estimate

Clinical Validation Status

Advantages for Neurodevelopmental Epilepsy

Developmental Window Consideration

Safety Advantages

Key Companies in RNA Editing

ProMis Neuroscience

Shape Therapeutics

Rewind Therapeutics

Korro Bio

Ascidian Therapeutics

Challenges and Future Directions

Current Challenges

Emerging Solutions

Future Directions

Key Publications

See Also

💬 Discussion

📗 Cite This Artifact

RNA Editing Therapeutics

RNA Editing Therapeutics

Overview

RNA Editing Therapeutics

Overview

Key RNA Editing Platforms

ADAR-Mediated Editing (A→I Conversion)

RESTORE Platform

CRISPR-Cas13-Based RNA Editing

C-to-U Editing (Cytidine Deaminase)

Delivery Challenges for CNS Applications

Blood-Brain Barrier Penetration

Chemical Modification Strategies

Comparison of Delivery Approaches

Therapeutic Applications

Neurology and Epilepsy

Comparison: RNA Editing vs. Alternative Modalities

Pipeline and Clinical Development

Timeline Estimate

Clinical Validation Status

Advantages for Neurodevelopmental Epilepsy

Developmental Window Consideration

Safety Advantages

Key Companies in RNA Editing

ProMis Neuroscience

Shape Therapeutics

Rewind Therapeutics

Korro Bio

Ascidian Therapeutics

Challenges and Future Directions

Current Challenges

Emerging Solutions

Future Directions

Key Publications

See Also

Related Hypotheses

💬 Discussion